Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Huvepharma Inc. currently manages its patent interests within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which represents the current focus of the company's active prosecution. This single matter is assigned to 1 distinct examiner, HAUK TEODORO, PRICILA NMN, who is responsible for the review of the technical claims. The prosecution is conducted within a distinct art unit, indicating a specific technical classification for the pending application.
The busiest examiner, HAUK TEODORO, PRICILA NMN, is currently managing the 1 pending office action. This creates a highly concentrated prosecution environment where the immediate outcome of the company's patent strategy depends on the review of a single individual. For practitioners, this concentration suggests that the prosecution approach must be precisely tailored to the specific feedback and requirements of this one examiner. The lack of distribution across multiple examiners or art units indicates a singular path through the examination process, requiring a focused effort to address the specific concerns raised in the biotechnology and pharmaceutical sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19082476 | RECOMBINANT ATTENUATED SALMONELLA VACCINES (RASVS) AGAINST INFECTIONS BY AVIAN PATHOGENIC ESCHERICHIA COLI (APEC) | HAUK TEODORO, PRICILA NMN | 1645 | §103 | Non-Final OA | — | Pending | Mar 18, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuvepharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Pricila Nmn Hauk Teodoro has the most, with 1 of Huvepharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
